Boehringer Ingelheim and Pfizer have developed a unique continuous bioprocess consisting of a short duration perfusion upstream and fully integrated downstream. The process is designed to generate at least 1 kg of material from a 100 L bioreactor in approximate 2 weeks. The upstream strategy utilizes a non-steady state, short duration perfusion process to achieve volumetric productivities ranging from 0.5 to 4 g/L/day. This creates a unique challenge for the downstream process as the titer and impurity load change over the duration of the culture.
展开▼
机译：Boehringer Ingelheim和Pfizer开发了一种独特的连续生物过程，包括上游的短持续时间灌注，并完全集成在下游。该过程被设计成在近似2周的100μl生物反应器中产生至少1kg材料。上游策略利用非稳态，短持续时间灌注过程，以实现从0.5至4g / l /天的体积生产率。这为下游进程创造了一个独特的挑战，因为在文化期间的滴度和杂质负荷变化。
展开▼
